TP53 Mutation Analysis
To detect and type mutations in the DNA-binding domain of the TP53 tumor suppressor gene for diagnosis of Li-Fraumeni syndrome and for prognosis and therapy selection of a wide range of cancer types.
This test is performed by PCR-based Sanger sequencing of DNA to examine the mutation status of exons 4 through 9 of TP53.
This assay can detect mutations present in exons 4, 5, 6, 7, 8 and 9 of TP53. The sensitivity of the Sanger sequencing assay is 20% of variant sequence in the background of wild-type sequence.
10 mL peripheral blood, 2-5mL bone marrow aspirate, 5g purified DNA, or 4-10 unstained tissue sections on glass slides along with 1 H&E-stained section.
Please provide a copy of the corresponding pathology report.
Additional charges may apply for tissue extraction.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.